Is the Price Right for Novo Nordisk?

Despite receiving approvals in the EU and Japan, Novo Nordisk's (NYSE: NVO  ) new insulin products Tresiba and Ryzodeg were given the red light by the FDA last week. Investors were shocked to hear the news, considering that an advisory committee that convened ahead of the official decision voted 8-4 in favor of approving the drug. Nevertheless, Novo Nordisk now has to complete a cardiovascular outcomes study in order to refile its NDAs for approval. In the meantime, Lantus, the long-acting insulin made by Sanofi (NYSE: SNY  ) , is set to continue its market dominance.

Reuters, however, recently reported that Novo Nordisk is planning on selling Tresiba at a higher price than Lantus in the U.K. In this video, health care analyst Max Macaluso discusses what this means for the company and how it can justify the higher price.

The future of MannKind?
Novo Nordisk and Sanofi are two established players in the diabetes space, but a small biotech company called MannKind is trying to revolutionize the way diabetes is treated around the world. But will the FDA put the kibosh on this product before it even hits the market? In a new premium research report on MannKind, these complex issues are made crystal clear, in addition to showing you why to buy or sell the stock today. To find out more -- and get a full year of free updates -- click here to grab your copy today.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2269457, ~/Articles/ArticleHandler.aspx, 4/18/2014 12:18:56 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement